open access

Ahead of print
Invited review article
Published online: 2020-10-15
Submitted: 2020-08-11
Accepted: 2020-09-07
Get Citation

Gastrostomy and mechanical ventilation in amyotrophic lateral sclerosis: how best to support the decision-making process?

Krzysztof Barć, Magdalena Kuźma-Kozakiewicz
DOI: 10.5603/PJNNS.a2020.0081
·
Pubmed: 33058114

open access

Ahead of print
Invited review article
Published online: 2020-10-15
Submitted: 2020-08-11
Accepted: 2020-09-07

Abstract

The unfavourable outcome of amyotrophic lateral sclerosis (ALS) confronts patients with challenging decisions regarding life-sustaining measures. The decision-making process is usually triggered by medical consultations and patient-dependent factors. This may largely depend on the physician’s depth of knowledge and professional experience. This paper presents an overview of the life-sustaining methods used in ALS and their effects on disease progression, survival and quality of life of patients and their caregivers. It is intended to aid physicians in their discussions with patients. We interrogate all the positive and negative facets of life-sustaining measures that may allow for optimisation of the decision-making process and care provision.

Abstract

The unfavourable outcome of amyotrophic lateral sclerosis (ALS) confronts patients with challenging decisions regarding life-sustaining measures. The decision-making process is usually triggered by medical consultations and patient-dependent factors. This may largely depend on the physician’s depth of knowledge and professional experience. This paper presents an overview of the life-sustaining methods used in ALS and their effects on disease progression, survival and quality of life of patients and their caregivers. It is intended to aid physicians in their discussions with patients. We interrogate all the positive and negative facets of life-sustaining measures that may allow for optimisation of the decision-making process and care provision.

Get Citation

Keywords

amyotrophic lateral sclerosis, therapeutic strategies, gastrostomy, mechanical ventilation, quality of life, survival

Supplementary Files (3)
Table 3
Download
29KB
Table 4
Download
30KB
Table 5
Download
26KB
About this article
Title

Gastrostomy and mechanical ventilation in amyotrophic lateral sclerosis: how best to support the decision-making process?

Journal

Neurologia i Neurochirurgia Polska

Issue

Ahead of print

Published online

2020-10-15

DOI

10.5603/PJNNS.a2020.0081

Pubmed

33058114

Keywords

amyotrophic lateral sclerosis
therapeutic strategies
gastrostomy
mechanical ventilation
quality of life
survival

Authors

Krzysztof Barć
Magdalena Kuźma-Kozakiewicz

References (137)
  1. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009; 4: 3.
  2. Kuźma-Kozakiewicz M. Edaravone in the treatment of amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2018; 52(2): 124–128.
  3. Lavernhe S, Antoine JC, Court-Fortune I, et al. Home care organization impacts patient management and survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(7-8): 562–568.
  4. Andersen PM, Kuzma-Kozakiewicz M, Keller J, et al. Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. J Neurol. 2018; 265(7): 1600–1606.
  5. Lulé D, Nonnenmacher S, Sorg S, et al. Live and let die: existential decision processes in a fatal disease. J Neurol. 2014; 261(3): 518–525.
  6. McGeachan AJ, Hobson EV, Al-Chalabi A, et al. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016; 12(9): 526–538.
  7. World Health Organization. The World Health Organization Quality of Life Assessment. Field Trial Version for Adults. Administration Manual. Geneva: World Health Organization. ; 1995.
  8. World Health Organization. WHOQoL: measuring quality of life. Geneva: World Health Organization. ; 1997.
  9. Goldstein LH, Atkins L, Leigh PN. Correlates of Quality of Life in people with motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2002; 3(3): 123–129.
  10. Simmons Z, Bremer BA, Robbins RA, et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology. 2000; 55(3): 388–392.
  11. Robbins RA, Simmons Z, Bremer BA, et al. Quality of life in ALS is maintained as physical function declines. Neurology. 2001; 56(4): 442–444.
  12. Neudert C, Wasner M, Borasio GD. Patients' assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001; 191(1-2): 103–109.
  13. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology. 1999; 52(7): 1434–1440.
  14. Clarke S, Hickey A, O'Boyle C, et al. Assessing individual quality of life in amyotrophic lateral sclerosis. Qual Life Res. 2001; 10(2): 149–158.
  15. Lulé D, Zickler C, Häcker S, et al. Life can be worth living in locked-in syndrome. Prog Brain Res. 2009; 177: 339–351.
  16. Kuzma-Kozakiewicz M, Andersen PM, Ciecwierska K, et al. An observational study on quality of life and preferences to sustain life in locked-in state. Neurology. 2019; 93(10): e938–e945.
  17. Körner S, Hendricks M, Kollewe K, et al. Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol. 2013; 13: 84.
  18. Desport JC, Preux PM, Truong CT, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999; 53(5): 1059–1063.
  19. Desport JC, Preux PM, Truong CT, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999; 53(5): 1059–1063.
  20. Bouteloup C, Desport JC, Clavelou P, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009; 256(8): 1236–1242.
  21. Vaisman N, Lusaus M, Nefussy B, et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci. 2009; 279(1-2): 26–29.
  22. Desport JC, Torny F, Lacoste M, et al. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis. 2005; 2(3-4): 202–207.
  23. Jeejeebhoy KN. Muscle function and nutrition. Gut. 1986; 27 Suppl 1: 25–39.
  24. Lopes J, Russell DM, Whitwell J, et al. Skeletal muscle function in malnutrition. Am J Clin Nutr. 1982; 36(4): 602–610.
  25. Andersen PM, Abrahams S, Borasio GD, et al. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012; 19(3): 360–375.
  26. Scott AG, Austin HE. Nasogastric feeding in the management of severe dysphagia in motor neurone disease. Palliat Med. 1994; 8(1): 45–49.
  27. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. The Lancet Neurology. 2015; 14(7): 702–709.
  28. Mazzini L, Corrà T, Zaccala M, et al. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol. 1995; 242(10): 695–698.
  29. Bokuda K, Shimizu T, Imamura K, et al. Predictive factors for prognosis following unsedated percutaneous endoscopic gastrostomy in ALS patients. Muscle Nerve. 2016; 54(2): 277–283.
  30. Kasarskis EJ, Scarlata D, Hill R, et al. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci. 1999; 169(1-2): 118–125.
  31. Allen JA, Chen R, Ajroud-Driss S, et al. Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: a retrospective study of complications and outcome. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14(4): 308–314.
  32. Blondet A, Lebigot J, Nicolas G, et al. Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy, and survival. J Vasc Interv Radiol. 2010; 21(4): 527–533.
  33. Thornton FJ, Fotheringham T, Haslam PJ, et al. Amyotrophic lateral sclerosis: enteral nutrition provision--endoscopic or radiologic gastrostomy? Radiology. 2002; 224(3): 713–717.
  34. Chiò A, Galletti R, Finocchiaro C, et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry. 2004; 75(4): 645–647.
  35. Shaw AS, Ampong MA, Rio A, et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler. 2006; 7(1): 16–21.
  36. Yang B, Shi X. Percutaneous endoscopic gastrostomy versus fluoroscopic gastrostomy in amyotrophic lateral sclerosis (ALS) sufferers with nutritional impairment: A meta-analysis of current studies. Oncotarget. 2017; 8(60): 102244–102253.
  37. Sancho J, Servera E, Chiner E, et al. Noninvasive respiratory muscle aids during PEG placement in ALS patients with severe ventilatory impairment. J Neurol Sci. 2010; 297(1-2): 55–59.
  38. Czell D, Bauer M, Binek J, et al. Outcomes of percutaneous endoscopic gastrostomy tube insertion in respiratory impaired amyotrophic lateral sclerosis patients under noninvasive ventilation. Respir Care. 2013; 58(5): 838–844.
  39. Desport JC, Mabrouk T, Bouillet P, et al. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6(2): 88–93.
  40. Barć K, Weber C, Maksymowicz-Śliwińska A, et al. Healthcare provision in amyotrophic lateral sclerosis: procedures, queries and pitfalls in Germany and Poland. Amyotroph Lateral Scler Frontotemporal Degener. 2020; 21(3-4): 193–202.
  41. Albert SM, Murphy PL, Del Bene M, et al. Incidence and predictors of PEG placement in ALS/MND. J Neurol Sci. 2001; 191(1-2): 115–119.
  42. Zhang L, Sanders L, Fraser RJL. Nutritional support teams increase percutaneous endoscopic gastrostomy uptake in motor neuron disease. World J Gastroenterol. 2012; 18(44): 6461–7; discussion p.6466.
  43. Mitsumoto H, Davidson M, Moore D, et al. ALS CARE Study Group. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4(3): 177–185.
  44. Dupuis L, Pradat PF, Ludolph A, et al. Energy metabolism in amyotrophic lateral sclerosis. The Lancet Neurology. 2011; 10(1): 75–82.
  45. Rosenfeld J, Ellis A. Nutrition and dietary supplements in motor neuron disease. Phys Med Rehabil Clin N Am. 2008; 19(3): 573–89, x.
  46. Paganoni S, Deng J, Jaffa M, et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011; 44(1): 20–24.
  47. Chiò A, Finocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group. Neurology. 1999; 53(5): 1123–1125.
  48. Dorst J, Dupuis L, Petri S, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol. 2015; 262(4): 849–858.
  49. Del Pi, Occhipinti P, Orsello M, et al. Percutaneous endoscopic gastrostomy (PEG) reduces complications and improves survival in amyotrophic lateral sclerosis (ALS). Gastrointest Endosc. 1999; 49: AB192.
  50. Reich-Slotky R, Andrews J, Cheng B, et al. Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14(3): 212–216.
  51. Ngo ST, Steyn FJ, McCombe PA. Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. J Neurol Sci. 2014; 340(1-2): 5–12.
  52. Mathus-Vliegen LM, Louwerse LS, Merkus MP, et al. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc. 1994; 40(4): 463–469.
  53. Salachas F, Fourmestraux AR, Le Fo, et al. Gastrostomy in patients with amyotrophic lateral sclerosis: a retrospective study in 110 patients. in: 7th International Symposium on ALS/MND, Chicago. : IL1996.
  54. Forbes RB, Colville S, Swingler RJ, et al. Scottish Motor Neurone Disease Research Group. Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease--a record linkage study from the Scottish Motor Neurone Disease Register. J Neurol. 2004; 251(7): 813–817.
  55. Miller RG, Jackson CE, Kasarskis EJ, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009; 73(15): 1218–1226.
  56. Finocchiaro E, Point MCDa, Chid A, et al. P.28 Percutaneous endoscopic gastrostomy inpatients with amyotrophic lateral sclerosis. Clinical Nutrition. 1998; 17: 37.
  57. Chiò A, Ilardi A, Cammarosano S, et al. Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology. 2012; 78(14): 1085–1089.
  58. Strong MJ, Rowe A, Rankin RN. Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis. J Neurol Sci. 1999; 169(1-2): 128–132.
  59. Mitchell SL, Tetroe JM. Survival after percutaneous endoscopic gastrostomy placement in older persons. J Gerontol A Biol Sci Med Sci. 2000; 55(12): M735–M739.
  60. Spataro R, Ficano L, Piccoli F, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci. 2011; 304(1-2): 44–48.
  61. Cui F, Sun L, Xiong J, et al. Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: A meta-analysis. PLoS One. 2018; 13(2): e0192243.
  62. Zamietra K, Lehman EB, Felgoise SH, et al. Non-invasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS. Amyotroph Lateral Scler. 2012; 13(1): 55–58.
  63. Trail M, Nelson ND, Van JN, et al. A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options. J Neurol Sci. 2003; 209(1-2): 79–85.
  64. Lo Coco D, Marchese S, Corrao S, et al. Development of chronic hypoventilation in amyotrophic lateral sclerosis patients. Respir Med. 2006; 100(6): 1028–1036.
  65. Kaplan LM, Hollander D. Respiratory dysfunction in amyotrophic lateral sclerosis. Clin Chest Med. 1994; 15(4): 675–681.
  66. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999; 52(7): 1311–1323.
  67. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998; 50(1): 66–72.
  68. Kleopa KA, Sherman M, Neal B, et al. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci. 1999; 164(1): 82–88.
  69. Morgan RK, McNally S, Alexander M, et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2005; 171(3): 269–274.
  70. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. Chest. 1999; 116(2): 521–534.
  71. Jackson CE, Rosenfeld J, Moore DH, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci. 2001; 191(1-2): 75–78.
  72. Allen SM, Hunt B, Green M. Fall in vital capacity with posture. Br J Dis Chest. 1985; 79(3): 267–271.
  73. Fallat RJ, Jewitt B, Bass M, et al. Spirometry in amyotrophic lateral sclerosis. Arch Neurol. 1979; 36(2): 74–80.
  74. Nickol AH, Hart N, Hopkinson NS, et al. Mechanisms of improvement of respiratory failure in patients with restrictive thoracic disease treated with non-invasive ventilation. Thorax. 2005; 60(9): 754–760.
  75. Gonzalez-Bermejo J, Morelot-Panzini C, Arnol N, et al. Prognostic value of efficiently correcting nocturnal desaturations after one month of non-invasive ventilation in amyotrophic lateral sclerosis: a retrospective monocentre observational cohort study. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14(5-6): 373–379.
  76. Aboussouan LS, Khan SU, Banerjee M, et al. Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve. 2001; 24(3): 403–409, doi: 10.1002/1097-4598(200103)24:3<403::aid-mus1013>3.0.co;2-3.
  77. Gruis KL, Brown DL, Schoennemann A, et al. Predictors of noninvasive ventilation tolerance in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2005; 32(6): 808–811.
  78. Sheers N, Berlowitz DJ, Rautela L, et al. Improved survival with an ambulatory model of non-invasive ventilation implementation in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(3-4): 180–184.
  79. Bertella E, Banfi P, Paneroni M, et al. Early initiation of night-time NIV in an outpatient setting: a randomized non-inferiority study in ALS patients. Eur J Phys Rehabil Med. 2017; 53(6): 892–899.
  80. Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006; 5(2): 140–147.
  81. Pinto AC, Evangelista T, Carvalho M, et al. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: Survival rates in a controlled trial. Journal of the Neurological Sciences. 1995; 129: 19–26.
  82. Burkhardt C, Neuwirth C, Sommacal A, et al. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS One. 2017; 12(5): e0177555.
  83. Lechtzin N, Scott Y, Busse AM, et al. Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph Lateral Scler. 2007; 8(3): 185–188.
  84. Pinto A, de Carvalho M, Evangelista T, et al. Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4(1): 31–35.
  85. Mustfa N, Walsh E, Bryant V, et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology. 2006; 66(8): 1211–1217.
  86. Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS. Neurology. 2001; 57(11): 2040–2044.
  87. Newsom-Davis IC, Lyall RA, Leigh PN, et al. The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry. 2001; 71(4): 482–487.
  88. Bourke SC, Bullock RE, Williams TL, et al. Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology. 2003; 61(2): 171–177.
  89. Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology. 2006; 67(5): 761–765.
  90. Mahajan KR, Bach JR, Saporito L, et al. Diaphragm pacing and noninvasive respiratory management of amyotrophic lateral sclerosis/motor neuron disease. Muscle Nerve. 2012; 46(6): 851–855.
  91. Schiffman P, Belsh J. Pulmonary Function at Diagnosis of Amyotrophic Lateral Sclerosis. Chest. 1993; 103(2): 508–513.
  92. Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017; 10: CD004427.
  93. Mizutani T, Aki M, Shiozawa R, et al. Development of ophthalmoplegia in amyotrophic lateral sclerosis during long-term use of respirators. J Neurol Sci. 1990; 99(2-3): 311–319.
  94. Kawata A, Mizoguchi K, Hayashi H. [A nationwide survey of ALS patients on trachoestomy positive pressure ventilation (TPPV) who developed a totally locked-in state (TLS) in Japan]. Rinsho Shinkeigaku. 2008; 48(7): 476–480.
  95. Moss AH, Oppenheimer EA, Casey P, et al. Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes. Chest. 1996; 110(1): 249–255.
  96. Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci. 1996; 139 Suppl: 123–128.
  97. Kaub-Wittemer D, Steinbüchel Nv, Wasner M, et al. Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. J Pain Symptom Manage. 2003; 26(4): 890–896.
  98. Hirano YM, Yamazaki Y, Shimizu J, et al. Ventilator dependence and expressions of need: a study of patients with amyotrophic lateral sclerosis in Japan. Soc Sci Med. 2006; 62(6): 1403–1413.
  99. Sancho J, Servera E, Bañuls P, et al. Prolonging survival in amyotrophic lateral sclerosis: efficacy of noninvasive ventilation and uncuffed tracheostomy tubes. Am J Phys Med Rehabil. 2010; 89(5): 407–411.
  100. Chiò A, Calvo A, Ghiglione P, et al. PARALS. Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. J Neurol Neurosurg Psychiatry. 2010; 81(10): 1141–1143.
  101. Vianello A, Arcaro G, Palmieri A, et al. Survival and quality of life after tracheostomy for acute respiratory failure in patients with amyotrophic lateral sclerosis. J Crit Care. 2011; 26(3): 329.e7–329.14.
  102. Sancho J, Servera E, Díaz JL, et al. Home tracheotomy mechanical ventilation in patients with amyotrophic lateral sclerosis: causes, complications and 1-year survival. Thorax. 2011; 66(11): 948–952.
  103. Lo Coco D, Marchese S, La Bella V, et al. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation. Chest. 2007; 132(1): 64–69.
  104. Spataro R, Bono V, Marchese S, et al. Tracheostomy mechanical ventilation in patients with amyotrophic lateral sclerosis: clinical features and survival analysis. J Neurol Sci. 2012; 323(1-2): 66–70.
  105. Laub M, Midgren B. Survival of patients on home mechanical ventilation: a nationwide prospective study. Respir Med. 2007; 101(6): 1074–1078.
  106. Rabkin JG, Albert SM, Tider T, et al. Predictors and course of elective long-term mechanical ventilation: A prospective study of ALS patients. Amyotroph Lateral Scler. 2006; 7(2): 86–95.
  107. Albert SM, Whitaker A, Rabkin JG, et al. Medical and supportive care among people with ALS in the months before death or tracheostomy. J Pain Symptom Manage. 2009; 38(4): 546–553.
  108. Rabkin JG, Albert SM, Rowland LP, et al. How common is depression among ALS caregivers? A longitudinal study. Amyotroph Lateral Scler. 2009; 10(5-6): 448–455.
  109. Tagami M, Kimura F, Nakajima H, et al. Tracheostomy and invasive ventilation in Japanese ALS patients: decision-making and survival analysis: 1990-2010. J Neurol Sci. 2014; 344(1-2): 158–164.
  110. Chiò A, Calvo A, Moglia C, et al. PARALS. Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study. J Neurol Neurosurg Psychiatry. 2012; 83(4): 377–381.
  111. Young JM, Marshall CL, Anderson EJ. Amyotrophic lateral sclerosis patients' perspectives on use of mechanical ventilation. Health Soc Work. 1994; 19(4): 253–260.
  112. Lyall R, Gelinas D. Control of symtoms: dysnoea and resiratory symtoms. In: Oliver DB, GD; Walsh, D, editor. Palliative care in amyotrohic lateral sclerosis From diagnosis to bereavement. Oxford: Oxford University Press; 2006. p. : 63–93.
  113. Borasio GD, Gelinas DF, Yanagisawa N. Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective. J Neurol. 1998; 245 Suppl 2: S7–12; discussion S29.
  114. Benjaminsen E, Alstadhaug KB, Gulsvik M, et al. Amyotrophic lateral sclerosis in Nordland county, Norway, 2000-2015: prevalence, incidence, and clinical features. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19(7-8): 522–527.
  115. O'Toole O, Traynor BJ, Brennan P, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry. 2008; 79(1): 30–32.
  116. Atsuta N, Watanabe H, Ito M, et al. Research Committee on the Neurodegenerative Diseases of Japan. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2009; 276(1-2): 163–169.
  117. Stoller JK, Xu M, Mascha E, et al. Long-term outcomes for patients discharged from a long-term hospital-based weaning unit. Chest. 2003; 124(5): 1892–1899.
  118. Bradley MD, Orrell RW, Clarke J, et al. Outcome of ventilatory support for acute respiratory failure in motor neurone disease. J Neurol Neurosurg Psychiatry. 2002; 72(6): 752–756.
  119. Nakayama Y, Shimizu T, Matsuda C, et al. Body weight variation predicts disease progression after invasive ventilation in amyotrophic lateral sclerosis. Sci Rep. 2019; 9(1): 12262.
  120. Rousseau MC, Pietra S, Blaya J, et al. Quality of life of ALS and LIS patients with and without invasive mechanical ventilation. J Neurol. 2011; 258(10): 1801–1804.
  121. Linse K, Rüger W, Joos M, et al. Eye-tracking-based assessment suggests preserved well-being in locked-in patients. Ann Neurol. 2017; 81(2): 310–315.
  122. Lulé D, Ehlich B, Lang D, et al. Quality of life in fatal disease: the flawed judgement of the social environment. J Neurol. 2013; 260(11): 2836–2843.
  123. Aho-Özhan HEA, Böhm S, Keller J, et al. Experience matters: neurologists' perspectives on ALS patients' well-being. J Neurol. 2017; 264(4): 639–646.
  124. Maessen M, Veldink JH, Onwuteaka-Philipsen BD, et al. Trends and determinants of end-of-life practices in ALS in the Netherlands. Neurology. 2009; 73(12): 954–961.
  125. Hecht M, Hillemacher T, Gräsel E, et al. Subjective experience and coping in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002; 3(4): 225–231.
  126. Kühnlein P, Kübler A, Raubold S, et al. Palliative care and circumstances of dying in German ALS patients using non-invasive ventilation. Amyotroph Lateral Scler. 2008; 9(2): 91–98.
  127. Stutzki R, Schneider U, Reiter-Theil S, et al. Attitudes Toward Assisted Suicide and Life-Prolonging Measures in Swiss ALS Patients and Their Caregivers. Front Psychol. 2012; 3: 443.
  128. Maessen M, Veldink JH, Onwuteaka-Philipsen BD, et al. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med. 2002; 346(21): 1638–1644.
  129. Leigh PN, Abrahams S, Al-Chalabi A, et al. King's MND Care and Research Team. The management of motor neurone disease. J Neurol Neurosurg Psychiatry. 2003; 74 Suppl 4: iv32–iv47.
  130. Aboussouan LS, Khan SU, Meeker DP, et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med. 1997; 127(6): 450–453.
  131. Elman LB, Siderowf AD, McCluskey LF. Nocturnal oximetry: utility in the respiratory management of amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2003; 82(11): 866–870.
  132. Sivak ED, Shefner JM, Mitsumoto H, et al. The use of non-invasive positive pressure ventilation (NIPPV) in ALS patients. A need for improved determination of intervention timing. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(3): 139–145.
  133. Morgan RK, McNally S, Alexander M, et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2005; 171(3): 269–274.
  134. Chiò A, Mora G, Leone M, et al. Piemonte and Valle d'Aosta Register for ALS (PARALS). Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002; 59(1): 99–103.
  135. Lyall RA, Donaldson N, Fleming T, et al. A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology. 2001; 57(1): 153–156.
  136. Bourke SC, Bullock RE, Williams TL, et al. Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology. 2003; 61(2): 171–177.
  137. Hein H, Schucher B, Magnussen H. Intermittierende Selbstbeatmung bei neuromuskulären Erkrankungen: Verlauf und Lebensqualität [Intermittent assisted ventilation in neuromuscular diseases: course and quality of life]. Pneumologie. 1999; 53(Suppl 2): S89–S90.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl